文献速递产科母胎医学

不明原因复发性流产妇女生殖结局的多中心观察研究:OTTILIA登记

Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry.
PubMed 文献 · Hum Reprod · 2021-01-01

该前瞻性多中心队列研究纳入不明原因复发性流产或宫内胎死腹中的孕妇,评估血栓形成倾向筛查及低分子肝素和/或低剂量阿司匹林治疗与生殖结局的关系。倾向评分匹配后265例孕妇中,77%获得活产,23%发生流产或胎死;血栓形成倾向与低分子肝素治疗存在显著交互作用(P=0.03),无治疗时血栓形成倾向者妊娠丢失OR为2.9(95%CI 1.4-6.1),低分子肝素(联合或不联合阿司匹林)与更高活产几率相关(OR 10.6,95%CI 5.0-22.3)。

要点

  • 不明原因复发性流产或胎死腹中孕妇常接受血栓形成倾向筛查,并常处方低分子肝素和/或阿司匹林。
  • 匹配样本中活产204例(77%),流产或胎死61例(23%)。
  • 血栓形成倾向与低分子肝素治疗存在显著交互作用(P=0.03)。

核心结论

  • 妊娠期抗血栓预防可能对不明原因妊娠丢失或胎死腹中的妇女有效,在血栓形成倾向者中可能更有用。

研究设计与样本

  • 前瞻性多中心队列研究,2012至2019年在三个国家12家医院开展。
  • 纳入连续妊娠的复发性妊娠丢失(≥3次丢失或至少1次整倍体胎儿核型时2次丢失)或至少1次宫内胎死腹中的妇女。
  • 采用倾向评分匹配平衡基线特征,匹配样本为265例孕妇。

主要发现

  • 匹配样本中所有孕妇均接受血栓形成倾向筛查;有血栓形成倾向者103/119(86.6%)和无血栓形成倾向者98/146(67.1%)被处方低分子肝素和/或阿司匹林。
  • 总体活产204例(77%),妊娠丢失或胎死腹中61例(23%)。
  • 逻辑回归显示血栓形成倾向与低分子肝素治疗间存在显著交互作用(P=0.03)。
  • 敏感性分析中,有遗传性或获得性血栓形成倾向且未治疗者妊娠丢失OR为2.9(95%CI 1.4-6.1)。
  • 低分子肝素(联合或不联合阿司匹林)与更高活产几率相关(OR 10.6,95%CI 5.0-22.3);无血栓形成倾向者中低分子肝素预防(单用或联合阿司匹林)与活产独立相关(OR 3.6,95%CI 1.7-7.9)。

临床怎么用

  • 对不明原因复发性流产或胎死腹中妇女可考虑血栓形成倾向筛查,并依据结果及当地实践评估抗血栓预防。
  • 低分子肝素联合或不联合阿司匹林可能与更高活产几率相关,但需结合个体情况权衡。

局限性

  • 倾向评分匹配虽可平衡基线特征差异,但不能消除所有混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What evaluation and care is offered to women after unexplained recurrent pregnancy loss (RPL) or intra-uterine foetal death (IUFD) and what are the reproductive outcomes? SUMMARY ANSWER: Women are assessed for thrombophilia and often treated with low-molecular weight heparin (LMWH) and/or low-dose aspirin (ASA). WHAT IS KNOWN ALREADY: Randomized controlled trials (RCTs) on possible efficacy of heparins and/or aspirin have been inconclusive due to limited power to detect a difference and patient heterogeneity. STUDY DESIGN, SIZE, DURATION: Prospective multicentre cohort study performed in 12 hospitals in three countries between 2012 and 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: All consecutive pregnant women with recurrent PL (≥3 losses or 2 losses in the presence of at least one euploid foetal karyotype) or at least one IUFD. Eligible women may have undergone thrombophilia testing before conception, at the discretion of local providers. The possible assignment of women to treatments (such as LMWH) was not decided a priori but was determined based on the responsible provider's current practice. Aims of the study were: (i) to evaluate factors associated with pregnancy outcome; (ii) to compare clinical management strategies in women with and without a subsequent successful pregnancy; and (iii) to evaluate characteristics of women who may benefit from antithrombotic therapy. A propensity score matching method was used to balance the differences in baseline characteristics. MAIN RESULTS AND THE ROLE OF CHANCE: A matched sample of 265 pregnant women was analysed, with all undergoing thrombophilia screening; 103 out of 119 (86.6%) with and 98/146 (67.1%) without thrombophilia were prescribed with LMWH and/or ASA. Overall, live-births were recorded in 204 cases (77%), PL or IUFD in 61 (23%) pregnancies. Logistic regression showed a significant interaction between thrombophilia and treatment with LMWH (P = 0.03). Findings from sensitivity analysis showed odds ratio (OR) for pregnancy loss in women with inherited or acquired thrombophilia in absence of any treatment was 2.9 (95% CI, 1.4-6.1); the administration of LMWH (with or without ASA) was associated with higher odds of live-birth (OR, 10.6; 95% CI, 5.0-22.3). Furthermore, in women without thrombophilia, the odds of live-birth was significantly and independently associated with LMWH prophylaxis (alone or in association with ASA) (OR, 3.6; 95% CI, 1.7-7.9). LIMITATIONS, REASONS FOR CAUTION: While the propensity score matching allows us to balance the differences in baseline characteristics, it does not eliminate all confounding. WIDER IMPLICATIONS OF THE FINDINGS: Antithrombotic prophylaxis during pregnancy may be effective in women with otherwise unexplained PL or IUFD, and even more useful in those with thrombophilia. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Italian Ministry of Health (Ricerca Corrente 2018-2020). Dr G.P. has received research grant support from Bristol Myers Squibb/Pfizer Alliance, Janssen, Boston Scientific Corporation, Bayer, and Portola and consultant fees from Amgen and Agile Therapeutics. Dr E.G. has received consultant fees from Italfarmaco and Sanofi. All other authors declare that they have no conflict of interest. TRIAL REGISTRATION NUMBER: NCT02385461.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Grandone E, Tiscia GL, Mastroianno M, et al. Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. Hum Reprod. 2021. PMID: 34195794. doi:10.1093/humrep/deab153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。